Novo Nordisk
Michael Hallgren is currently the Direktør/SVP at Novo Nordisk, overseeing the production of API. With a background in mechanical engineering, Michael has held various leadership positions within Novo Nordisk, including heading up production areas for purification of modern Insulin and managing the manufacturing of Insulin Aspart and Human Insulin. In addition to their role at Novo Nordisk, Michael has also served as a board member for various companies such as NNE, Kalundborg Symbiosis, Novo Nordisk Pharmatech A/S, and BIOPRO. Their expertise in production and deep involvement in industrial collaborations highlight their commitment to sustainable practices in the pharmaceutical industry.